These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 21340616)

  • 21. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
    Holst JJ; Buse JB; Rodbard HW; Linjawi S; Woo VC; Boesgaard TW; Kvist K; Gough SC
    J Diabetes Sci Technol; 2015 Oct; 10(2):389-97. PubMed ID: 26443290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.
    Katz LB; Gambale JJ; Rothenberg PL; Vanapalli SR; Vaccaro N; Xi L; Sarich TC; Stein PP
    Diabetes Obes Metab; 2012 Aug; 14(8):709-16. PubMed ID: 22340428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.
    Hjerpsted JB; Flint A; Brooks A; Axelsen MB; Kvist T; Blundell J
    Diabetes Obes Metab; 2018 Mar; 20(3):610-619. PubMed ID: 28941314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
    Madsbad S; Schmitz O; Ranstam J; Jakobsen G; Matthews DR;
    Diabetes Care; 2004 Jun; 27(6):1335-42. PubMed ID: 15161785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
    Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
    Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes.
    Matthews JE; Reinhardt RR; Carr MC
    Postgrad Med; 2016 May; 128(4):391-7. PubMed ID: 27043162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
    Flint A; Kapitza C; Zdravkovic M
    Diabetes Obes Metab; 2013 Oct; 15(10):958-62. PubMed ID: 23551925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
    Kapitza C; Forst T; Coester HV; Poitiers F; Ruus P; Hincelin-Méry A
    Diabetes Obes Metab; 2013 Jul; 15(7):642-9. PubMed ID: 23368510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation.
    Kuo P; Stevens JE; Russo A; Maddox A; Wishart JM; Jones KL; Greville H; Hetzel D; Chapman I; Horowitz M; Rayner CK
    J Clin Endocrinol Metab; 2011 May; 96(5):E851-5. PubMed ID: 21389144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial.
    Perano SJ; Couper JJ; Horowitz M; Martin AJ; Kritas S; Sullivan T; Rayner CK
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2486-93. PubMed ID: 24670086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monosodium glutamate stimulates secretion of glucagon-like peptide-1 and reduces postprandial glucose after a lipid-containing meal.
    Hosaka H; Kusano M; Zai H; Kawada A; Kuribayashi S; Shimoyama Y; Nagoshi A; Maeda M; Kawamura O; Mori M
    Aliment Pharmacol Ther; 2012 Nov; 36(9):895-903. PubMed ID: 22978669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
    Becker RH; Stechl J; Steinstraesser A; Golor G; Pellissier F
    Diabetes Metab Res Rev; 2015 Sep; 31(6):610-8. PubMed ID: 25773712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.
    Seino Y; Rasmussen MF; Zdravkovic M; Kaku K
    Diabetes Res Clin Pract; 2008 Aug; 81(2):161-8. PubMed ID: 18495285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
    Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
    Am J Clin Nutr; 2016 Jan; 103(1):66-70. PubMed ID: 26607942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.